Page 21 - Mousumi

Weaver Monomousumi.com

drugs, antibiotics, glucocorticoids, or after for patients. Third, we need to
traditional Chinese medicine. Despite spot and reduce transmission from
this, there have been reports of the the animal source or sources. Fourth,
use of oseltamivir, lopinavir/ritonavir, we need to address crucial
prednisone, antibiotics, and traditional uncertainties such as clinical severity,
Chinese medicine for the treatment of the extent of transmission and
patients with COVID-19. Care should infection, and treatment options, and
be taken to not give patients drugs of accelerate the development of
unknown efficacy, which might be diagnostics, therapeutics, and
detrimental to critically ill patients vaccines. We also need to minimize
with COVID-19; clinical trials are social disruption and economic
urgently required in this context. impact through international,
Likewise, the development of a collaborative, and multisectoral
vaccine is an urgent public health approaches. Most importantly, we
priority. need to communicate the
COVID-19 is an emerging infectious epidemiology and risks of COVID-
disease of global public health 19, both to health-care workers and
concern. Efforts to control the the general population, and to
COVID-19 epidemic are likely to implement infection prevention and
require an evidence-based, control measures that are based on
multifactorial approach. First, there is sound scientific principles.
a need to limit human-to-human
transmission, including reducing Hopefully, the lessons we would have
secondary infections among close learned about living within the
contacts and health-care workers, parameters defined by the lockdown
preventing transmission amplification without dependence on what was
events, and preventing further once unimaginable will stay with us.
international spread. Second, there is *****************************
a requirement to rapidly identify,
isolate, and supply optimized look

Page 19